{"id":838793,"date":"2026-09-29T18:51:01","date_gmt":"2026-09-29T18:51:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=838793"},"modified":"2026-09-29T18:51:01","modified_gmt":"2026-09-29T18:51:01","slug":"22q112-deletion-syndrome-market-rising-diagnostic-awareness-and-emerging-diseasespecific-therapies-to-transform-the-treatment-landscape-through-2036","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/22q112-deletion-syndrome-market-rising-diagnostic-awareness-and-emerging-diseasespecific-therapies-to-transform-the-treatment-landscape-through-2036_838793.html","title":{"rendered":"22q11.2 Deletion Syndrome Market: Rising Diagnostic Awareness and Emerging Disease-Specific Therapies to Transform the Treatment Landscape Through 2036"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1790664412.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"22q11.2 Deletion Syndrome Market: Rising Diagnostic Awareness and Emerging Disease-Specific Therapies to Transform the Treatment Landscape Through 2036\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/09\/1790664412.jpg\" alt=\"22q11.2 Deletion Syndrome Market: Rising Diagnostic Awareness and Emerging Disease-Specific Therapies to Transform the Treatment Landscape Through 2036\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The 22q11.2 Deletion Syndrome market is poised for significant evolution, driven by advancements in genetic testing and diagnosis, increasing awareness of rare genetic disorders, growing research &#038; development activities, supportive regulatory initiatives, and the need for multidisciplinary management of this complex chromosomal disorder. Emerging candidates such as NB-001 are being investigated to address neuropsychiatric manifestations and potentially expand disease-specific treatment options.<\/div>\n<p style=\"text-align: justify;\"><strong>New York, USA &ndash; September 29, 2026<\/strong> &ndash; The <strong>22q11.2 Deletion Syndrome market<\/strong> is poised for significant evolution, driven by advancements in genetic testing and diagnosis, increasing awareness of rare genetic disorders, growing research and development activities, supportive regulatory initiatives, and the need for multidisciplinary management of this complex chromosomal disorder. The therapeutic landscape remains largely supportive, with no broadly available disease-modifying therapy for the multisystem manifestations of 22q11.2 Deletion Syndrome. However, emerging candidates such as <strong>NB-001<\/strong> are being investigated to address neuropsychiatric manifestations and potentially expand disease-specific treatment options.<\/p>\n<p style=\"text-align: justify;\">According to DelveInsight, the <strong>22q11.2 Deletion Syndrome market was valued at approximately USD 14 million in 2025<\/strong> and is projected to grow at a <strong>CAGR of approximately 32% during 2026&ndash;2036<\/strong>. The market analysis covers the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s report, <strong>&ldquo;22q11.2 Deletion Syndrome Market Insights, Epidemiology and Market Forecast &ndash; 2036,&rdquo;<\/strong> provides comprehensive insights into disease epidemiology, patient burden, current treatment practices, emerging therapies, competitive landscape, market size, unmet needs, and future market opportunities across the seven major markets.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The <strong>7MM 22q11.2 Deletion Syndrome market size was approximately USD 14 million in 2025<\/strong>.<\/li>\n<li>The market is projected to grow at approximately <strong>32% CAGR from 2026 to 2036<\/strong>.<\/li>\n<li>Approximately <strong>101,500 diagnosed prevalent cases<\/strong> of 22q11.2 Deletion Syndrome were estimated across the 7MM in 2025.<\/li>\n<li>The <strong>United States accounted for the largest market<\/strong>, with a market size of approximately <strong>USD 8 million in 2025<\/strong>.<\/li>\n<li>In the US, approximately <strong>12,550 infant cases, 10,300 cases aged 1&ndash;5 years, 19,550 cases aged 6&ndash;12 years, 4,800 cases aged 13&ndash;17 years, and 7,000 adult cases<\/strong> were estimated among diagnosed prevalent patients in 2025.<\/li>\n<li>Germany had the highest diagnosed prevalent burden among the EU4 and UK, with approximately <strong>9,300 cases<\/strong> in 2025.<\/li>\n<li>Approximately <strong>7,650 cases with behavioral and psychiatric phenotypes<\/strong> were estimated in Japan in 2025.<\/li>\n<li>There are currently <strong>no FDA-approved disease-modifying therapies specifically addressing the broad multisystem manifestations<\/strong> of 22q11.2 Deletion Syndrome.<\/li>\n<li><strong>RETHYMIC<\/strong>, a thymus tissue-based regenerative therapy, is approved for congenital athymia, a severe immune deficiency frequently associated with 22q11.2 Deletion Syndrome.<\/li>\n<li><strong>NB-001 (fasoracetam)<\/strong> from Nobias Therapeutics represents an important investigational approach targeting neuropsychiatric manifestations associated with 22q11.2 Deletion Syndrome.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Keen to know more about the 22q11.2 Deletion Syndrome market? Request our sample page at: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/22q112-deletion-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/22q112-deletion-syndrome-market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving the 22q11.2 Deletion Syndrome Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Advancements in Genetic Testing and Diagnosis<\/strong><\/p>\n<p style=\"text-align: justify;\">Improved molecular diagnostic technologies are supporting earlier and more accurate identification of 22q11.2 Deletion Syndrome. Chromosomal microarray is described by DelveInsight as the current gold standard for genetic confirmation, while increasing use of genomic-first approaches and prenatal screening is contributing to improved detection.<\/p>\n<p style=\"text-align: justify;\"><strong>Increasing Awareness of Rare Genetic Disorders<\/strong><\/p>\n<p style=\"text-align: justify;\">Growing awareness among healthcare professionals, caregivers, and patient advocacy organizations is supporting recognition of the heterogeneous clinical presentation of 22q11.2 Deletion Syndrome. Greater disease awareness can contribute to improved diagnosis and identification of patients requiring multidisciplinary care.<\/p>\n<p style=\"text-align: justify;\"><strong>Growing Research and Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">Pharmaceutical and biotechnology companies are investigating targeted approaches for the disease and its associated neuropsychiatric and immune manifestations. The emergence of mechanism-based therapies such as NB-001 represents a shift beyond purely symptomatic treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>Supportive Government and Regulatory Initiatives<\/strong><\/p>\n<p style=\"text-align: justify;\">Orphan-drug incentives, rare-disease research funding, and regulatory programs designed to facilitate development of therapies for serious pediatric conditions can support investment in the 22q11.2 Deletion Syndrome therapeutic landscape. NB-001 has received FDA Rare Pediatric Disease designation, while Nobias Therapeutics has secured preliminary FDA alignment regarding registrational endpoints.<\/p>\n<p style=\"text-align: justify;\"><strong>Growing Demand for Multidisciplinary Care<\/strong><\/p>\n<p style=\"text-align: justify;\">The multisystem nature of 22q11.2 Deletion Syndrome requires coordination among cardiology, immunology, endocrinology, developmental medicine, neurology, and psychiatry. Increasing recognition of these long-term care requirements contributes to healthcare resource utilization and creates demand for more integrated management strategies.<\/p>\n<p style=\"text-align: justify;\"><strong>Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The 22q11.2 Deletion Syndrome competitive landscape consists of companies developing regenerative, small-molecule, and symptom-focused therapeutic approaches.<\/p>\n<p style=\"text-align: justify;\">Key companies include:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Sumitomo Pharma<\/strong><\/li>\n<li><strong>Enzyvant<\/strong><\/li>\n<li><strong>Roivant Sciences<\/strong><\/li>\n<li><strong>Zynerba Pharmaceuticals<\/strong><\/li>\n<li><strong>Harmony Biosciences<\/strong><\/li>\n<li><strong>Nobias Therapeutics<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The principal therapies highlighted by DelveInsight include <strong>RETHYMIC<\/strong> and the investigational <strong>NB-001<\/strong>, while Zygel (ZYN002) represents a previously investigated approach for behavioral symptoms whose development in 22q11.2 Deletion Syndrome has been paused.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to impact the 22q11.2 Deletion Syndrome market @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/22q112-deletion-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">DelveInsight &ndash; 22q11.2 Deletion Syndrome Market Insights<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Recent Developments in the 22q11.2 Deletion Syndrome Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>June 2025:<\/strong> Nobias Therapeutics secured preliminary alignment with the US FDA on registrational endpoints for <strong>NB-001<\/strong> for the treatment of neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome.<\/li>\n<li><strong>2025:<\/strong> Harmony Biosciences reported that development of <strong>Zygel (ZYN002)<\/strong> in 22q11.2 Deletion Syndrome had been paused pending a full review of RECONNECT data.<\/li>\n<li><strong>2021:<\/strong> RETHYMIC received FDA approval for immune reconstitution in pediatric patients with congenital athymia, addressing severe immune deficiency associated with complete DiGeorge syndrome\/anomaly.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>What is 22q11.2 Deletion Syndrome?<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22q11.2 Deletion Syndrome (22q11.2DS)<\/strong> is a chromosomal microdeletion disorder caused by deletion of genetic material at chromosome 22q11.2. It is also known as <strong>DiGeorge syndrome<\/strong> or <strong>velocardiofacial syndrome<\/strong>.<\/p>\n<p style=\"text-align: justify;\">The condition results from haploinsufficiency of several genes, including <strong>TBX1<\/strong>, and can affect multiple organ systems. Common manifestations include congenital heart defects, thymic hypoplasia and immune dysfunction, hypoparathyroidism-associated hypocalcemia, craniofacial abnormalities, developmental difficulties, learning disabilities, autism spectrum disorder, and psychiatric manifestations.<\/p>\n<p style=\"text-align: justify;\">DelveInsight estimates the prevalence at approximately <strong>1 in 3,000&ndash;4,000 live births<\/strong>, making 22q11.2 Deletion Syndrome the most common chromosomal microdeletion syndrome. The clinical presentation is highly variable, which contributes to underdiagnosis and delayed diagnosis, particularly among individuals without major congenital abnormalities.<\/p>\n<p style=\"text-align: justify;\">Diagnosis is generally confirmed through genetic testing, with <strong>chromosomal microarray (CMA)<\/strong> serving as the current gold-standard diagnostic approach described in the report.<\/p>\n<p style=\"text-align: justify;\"><strong>22q11.2 Deletion Syndrome Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The DelveInsight epidemiology assessment evaluates the 22q11.2 Deletion Syndrome patient population across several clinically relevant categories:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Total prevalent cases of 22q11.2 Deletion Syndrome<\/strong><\/li>\n<li><strong>Total diagnosed prevalent cases<\/strong><\/li>\n<li><strong>Age-specific diagnosed prevalent cases<\/strong><\/li>\n<li><strong>Diagnosed prevalent cases with behavioral and psychiatric phenotypes<\/strong><\/li>\n<li><strong>Total treated cases<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">According to DelveInsight&#8217;s estimates, approximately <strong>101,500 diagnosed prevalent cases<\/strong> of 22q11.2 Deletion Syndrome were present across the 7MM in 2025.<\/p>\n<p style=\"text-align: justify;\">In the United States, the age-specific diagnosed prevalent population in 2025 included approximately <strong>12,550 infants, 10,300 patients aged 1&ndash;5 years, 19,550 patients aged 6&ndash;12 years, 4,800 patients aged 13&ndash;17 years, and 7,000 adults<\/strong>.<\/p>\n<p style=\"text-align: justify;\">Among the EU4 and UK, <strong>Germany recorded approximately 9,300 diagnosed prevalent cases<\/strong>, representing the highest burden among those markets, while Spain had approximately 6,100 cases in 2025. Japan had approximately <strong>7,650 diagnosed prevalent cases with behavioral and psychiatric phenotypes<\/strong>.<\/p>\n<p style=\"text-align: justify;\"><strong>Current Treatment Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">There is currently no curative treatment addressing the underlying genetic defect across the broad spectrum of 22q11.2 Deletion Syndrome. Management remains <strong>supportive, symptom-driven, and multidisciplinary<\/strong>, with treatment tailored according to age, disease severity, and organ involvement.<\/p>\n<p style=\"text-align: justify;\"><strong>Management of Congenital Heart Defects<\/strong><\/p>\n<p style=\"text-align: justify;\">Patients with significant congenital heart abnormalities may require surgical correction or other cardiovascular interventions. Cardiac management is particularly important during infancy and early childhood.<\/p>\n<p style=\"text-align: justify;\"><strong>Management of Immune Dysfunction<\/strong><\/p>\n<p style=\"text-align: justify;\">Immune abnormalities may require infection prevention, antimicrobial management, immunoglobulin replacement in selected patients, and specialized immunological monitoring. For severe T-cell deficiency associated with congenital athymia, thymus transplantation may be considered.<\/p>\n<p style=\"text-align: justify;\"><strong>Management of Hypocalcemia<\/strong><\/p>\n<p style=\"text-align: justify;\">Hypoparathyroidism and hypocalcemia are managed through calcium and vitamin D supplementation and appropriate endocrine monitoring.<\/p>\n<p style=\"text-align: justify;\"><strong>Developmental and Psychiatric Management<\/strong><\/p>\n<p style=\"text-align: justify;\">Speech, occupational, behavioral, and developmental interventions are used to address neurodevelopmental difficulties. Psychiatric management may include treatment of ADHD, anxiety, and schizophrenia when these conditions occur.<\/p>\n<p style=\"text-align: justify;\"><strong>Approved Therapy<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>RETHYMIC &ndash; Sumitomo Pharma\/Enzyvant\/Roivant Sciences<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>RETHYMIC (formerly RVT-802)<\/strong> is a thymus tissue-based regenerative therapy indicated for patients with <strong>congenital athymia<\/strong>, a rare and life-threatening immune deficiency that can occur in association with 22q11.2 Deletion Syndrome.<\/p>\n<p style=\"text-align: justify;\">The therapy involves implantation of allogeneic cultured thymus tissue to restore T-cell development and immune function. According to the DelveInsight report, RETHYMIC was approved in <strong>2021<\/strong> and represents a disease-modifying treatment option for the severe immune-deficiency component of this patient population.<\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Therapy<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NB-001 (Fasoracetam) &ndash; Nobias Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>NB-001<\/strong>, also referred to as fasoracetam, is an investigational non-stimulant activator of multiple metabotropic glutamate receptors (mGluRs). It is being developed to target disrupted glutamatergic signaling associated with cognitive and psychiatric manifestations of 22q11.2 Deletion Syndrome.<\/p>\n<p style=\"text-align: justify;\">The therapy has completed a <strong>Phase II clinical trial<\/strong> and has received <strong>FDA Rare Pediatric Disease designation<\/strong>. In June 2025, Nobias Therapeutics reported preliminary alignment with the FDA regarding registrational endpoints, providing greater clarity for the potential development pathway of NB-001.<\/p>\n<p style=\"text-align: justify;\"><strong>Zygel (ZYN002) &ndash; Development Status<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Zygel (ZYN002)<\/strong>, a transdermal cannabidiol gel developed by Zynerba Pharmaceuticals, was investigated for behavioral symptoms associated with 22q11.2 Deletion Syndrome.<\/p>\n<p style=\"text-align: justify;\">The report notes that the development program was <strong>paused pending a full review of RECONNECT data<\/strong>. This leaves the asset as a previously investigated approach rather than an actively progressing disease-specific program in the current landscape described by DelveInsight.<\/p>\n<p style=\"text-align: justify;\"><strong>Unmet Needs in 22q11.2 Deletion Syndrome<\/strong><\/p>\n<p style=\"text-align: justify;\">Despite advances in diagnosis and supportive care, substantial unmet needs remain across the 22q11.2 Deletion Syndrome treatment landscape.<\/p>\n<p style=\"text-align: justify;\">Key unmet needs include:<\/p>\n<ol style=\"text-align: justify;\">\n<li><strong>Lack of FDA-approved disease-specific therapies for the broader syndrome<\/strong><\/li>\n<li><strong>High risk of neurological and psychiatric disorders<\/strong><\/li>\n<li><strong>Diagnostic delays and hidden disease burden<\/strong><\/li>\n<li><strong>Lack of standardized lifespan management frameworks<\/strong><\/li>\n<li><strong>Limited disease-modifying treatment options<\/strong><\/li>\n<li><strong>Need for therapies targeting neurodevelopmental and psychiatric manifestations<\/strong><\/li>\n<li><strong>Need for coordinated multidisciplinary care throughout the patient&#8217;s lifetime<\/strong><\/li>\n<\/ol>\n<p style=\"text-align: justify;\">The heterogeneous presentation of 22q11.2 Deletion Syndrome further complicates the development of standardized treatment pathways and contributes to variation in diagnosis and disease management.<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the 22q11.2 Deletion Syndrome Market Report<\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>22q11.2 Deletion Syndrome Market Report &ndash; 2036<\/strong> provides a comprehensive assessment of the disease and therapeutic landscape, including:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Historical and forecasted market size from <strong>2022&ndash;2036<\/strong><\/li>\n<li>Epidemiological assessment across the 7MM<\/li>\n<li>Total and diagnosed prevalent populations<\/li>\n<li>Age-specific patient analysis<\/li>\n<li>Behavioral and psychiatric phenotype assessment<\/li>\n<li>Treated patient population<\/li>\n<li>Current treatment practices and treatment algorithms<\/li>\n<li>Marketed and emerging therapies<\/li>\n<li>Clinical development and pipeline analysis<\/li>\n<li>Competitive landscape<\/li>\n<li>Market drivers and barriers<\/li>\n<li>Unmet medical needs<\/li>\n<li>Drug uptake and peak patient-share analysis<\/li>\n<li>Pricing and analogue assessment<\/li>\n<li>Reimbursement and market-access analysis<\/li>\n<li>KOL and physician insights<\/li>\n<li>SWOT and conjoint analysis<\/li>\n<li>Market opportunity assessment<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report covers the <strong>United States, Germany, France, Italy, Spain, the United Kingdom, and Japan<\/strong>, with the historical period covering 2022&ndash;2025 and the forecast period spanning 2026&ndash;2036.<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about 22q11.2 Deletion Syndrome companies and emerging therapies, request a sample copy of the report: <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/22q112-deletion-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">Request Sample Report<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>Key Insights<\/li>\n<li>Report Introduction<\/li>\n<li>Executive Summary of 22q11.2 Deletion Syndrome<\/li>\n<li>Key Events<\/li>\n<li>Epidemiology and Market Forecast Methodology<\/li>\n<li>22q11.2 Deletion Syndrome Market Overview at a Glance<\/li>\n<li>Disease Background and Overview<\/li>\n<li>Treatment<\/li>\n<li>Epidemiology and Patient Population<\/li>\n<li>Drug Analysis and Competitive Landscape<\/li>\n<li>Approved Therapies<\/li>\n<li>Emerging Therapies<\/li>\n<li>Drug Uptake and Market Forecast<\/li>\n<li>Market Access and Reimbursement<\/li>\n<li>Pricing and Analogue Assessment<\/li>\n<li>Industry Expert and Physician Views<\/li>\n<li>SWOT and Conjoint Analysis<\/li>\n<li>Market Drivers and Barriers<\/li>\n<li>Unmet Needs<\/li>\n<li>Market Opportunity and Future Outlook<\/li>\n<li>Report Scope and Methodology<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=22q112-deletion-syndrome-market-rising-diagnostic-awareness-and-emerging-diseasespecific-therapies-to-transform-the-treatment-landscape-through-2036\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=22q112-deletion-syndrome-market-rising-diagnostic-awareness-and-emerging-diseasespecific-therapies-to-transform-the-treatment-landscape-through-2036\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The 22q11.2 Deletion Syndrome market is poised for significant evolution, driven by advancements in genetic testing and diagnosis, increasing awareness of rare genetic disorders, growing research &#038; development activities, supportive regulatory initiatives, and the need for multidisciplinary management of this &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/22q112-deletion-syndrome-market-rising-diagnostic-awareness-and-emerging-diseasespecific-therapies-to-transform-the-treatment-landscape-through-2036_838793.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-838793","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/838793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=838793"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/838793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=838793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=838793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=838793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}